Correction: Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial

Detalles Bibliográficos
Autores principales: Yamauchi, Hideko, Toi, Masakazu, Takayama, Shin, Nakamura, Seigo, Takano, Toshimi, Cui, Karen, Campbell, Christine, De Vos, Liesbet, Geyer, Charles, Tutt, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285017/
https://www.ncbi.nlm.nih.gov/pubmed/37171785
http://dx.doi.org/10.1007/s12282-023-01468-z
_version_ 1785061519404302336
author Yamauchi, Hideko
Toi, Masakazu
Takayama, Shin
Nakamura, Seigo
Takano, Toshimi
Cui, Karen
Campbell, Christine
De Vos, Liesbet
Geyer, Charles
Tutt, Andrew
author_facet Yamauchi, Hideko
Toi, Masakazu
Takayama, Shin
Nakamura, Seigo
Takano, Toshimi
Cui, Karen
Campbell, Christine
De Vos, Liesbet
Geyer, Charles
Tutt, Andrew
author_sort Yamauchi, Hideko
collection PubMed
description
format Online
Article
Text
id pubmed-10285017
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Nature Singapore
record_format MEDLINE/PubMed
spelling pubmed-102850172023-06-23 Correction: Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial Yamauchi, Hideko Toi, Masakazu Takayama, Shin Nakamura, Seigo Takano, Toshimi Cui, Karen Campbell, Christine De Vos, Liesbet Geyer, Charles Tutt, Andrew Breast Cancer Correction Springer Nature Singapore 2023-05-12 2023 /pmc/articles/PMC10285017/ /pubmed/37171785 http://dx.doi.org/10.1007/s12282-023-01468-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Correction
Yamauchi, Hideko
Toi, Masakazu
Takayama, Shin
Nakamura, Seigo
Takano, Toshimi
Cui, Karen
Campbell, Christine
De Vos, Liesbet
Geyer, Charles
Tutt, Andrew
Correction: Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial
title Correction: Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial
title_full Correction: Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial
title_fullStr Correction: Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial
title_full_unstemmed Correction: Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial
title_short Correction: Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial
title_sort correction: adjuvant olaparib in the subset of patients from japan with brca1- or brca2-mutated high-risk early breast cancer from the phase 3 olympia trial
topic Correction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285017/
https://www.ncbi.nlm.nih.gov/pubmed/37171785
http://dx.doi.org/10.1007/s12282-023-01468-z
work_keys_str_mv AT yamauchihideko correctionadjuvantolaparibinthesubsetofpatientsfromjapanwithbrca1orbrca2mutatedhighriskearlybreastcancerfromthephase3olympiatrial
AT toimasakazu correctionadjuvantolaparibinthesubsetofpatientsfromjapanwithbrca1orbrca2mutatedhighriskearlybreastcancerfromthephase3olympiatrial
AT takayamashin correctionadjuvantolaparibinthesubsetofpatientsfromjapanwithbrca1orbrca2mutatedhighriskearlybreastcancerfromthephase3olympiatrial
AT nakamuraseigo correctionadjuvantolaparibinthesubsetofpatientsfromjapanwithbrca1orbrca2mutatedhighriskearlybreastcancerfromthephase3olympiatrial
AT takanotoshimi correctionadjuvantolaparibinthesubsetofpatientsfromjapanwithbrca1orbrca2mutatedhighriskearlybreastcancerfromthephase3olympiatrial
AT cuikaren correctionadjuvantolaparibinthesubsetofpatientsfromjapanwithbrca1orbrca2mutatedhighriskearlybreastcancerfromthephase3olympiatrial
AT campbellchristine correctionadjuvantolaparibinthesubsetofpatientsfromjapanwithbrca1orbrca2mutatedhighriskearlybreastcancerfromthephase3olympiatrial
AT devosliesbet correctionadjuvantolaparibinthesubsetofpatientsfromjapanwithbrca1orbrca2mutatedhighriskearlybreastcancerfromthephase3olympiatrial
AT geyercharles correctionadjuvantolaparibinthesubsetofpatientsfromjapanwithbrca1orbrca2mutatedhighriskearlybreastcancerfromthephase3olympiatrial
AT tuttandrew correctionadjuvantolaparibinthesubsetofpatientsfromjapanwithbrca1orbrca2mutatedhighriskearlybreastcancerfromthephase3olympiatrial

Ejemplares similares